High-viscosity anti-swelling tissue adhesive based on dual-acceptor deep eutectic solvent and preparation method of high-viscosity anti-swelling tissue adhesive

By utilizing a high-viscosity, anti-swelling tissue adhesive based on a dual-receptor deep eutectic solvent, and employing hydrogen bonding and ring-opening polymerization technology, the problem of loss of existing adhesives in body fluid or blood environments has been solved, achieving a high-viscosity, anti-swelling, and biodegradable wound-closing effect.

CN121243447APending Publication Date: 2026-01-02CHANGCHUN INSTITUTE OF APPLIED CHEMISTRY CHINESE ACADEMY OF SCIENCES
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202511352800.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-09-22
Publication Date
2026-01-02

AI Technical Summary

Technical Problem

Existing injectable adhesives in the biomedical field suffer from problems such as low bonding strength, poor biodegradability, and insufficient anti-swelling properties. In particular, they are easily washed away in bodily fluids or blood environments, affecting wound closure.

Method used

A high-viscosity anti-swelling tissue binder based on a dual-receptor deep eutectic solvent is used. A high-viscosity DES prepolymer is formed by combining cycloenol acetal monomers, initiators and crosslinking agents with olefin monomers, choline chloride and arginine. The high-viscosity binder is constructed by hydrogen bonding and combined with the ring-opening polymerization of CKA to form a hydrophobic network, thereby achieving anti-swelling and stability.

Benefits of technology

It provides a high-viscosity, anti-swelling, injectable adhesive that can effectively adhere to wound sites in the presence of body fluids or blood, achieving rapid wound closure and long-term stable adhesion. It is suitable for closing massive bleeding wounds, internal wounds, and bone tissue, and has excellent anti-swelling and tensile properties, and is degradable after tissue repair.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005606845500000071
    Figure BDA0005606845500000071
  • Figure BDA0005606845500000072
    Figure BDA0005606845500000072
  • Figure BDA0005606845500000081
    Figure BDA0005606845500000081
Patent Text Reader

Abstract

The invention provides a high-viscosity anti-swelling tissue adhesive based on a dual-acceptor deep eutectic solvent as well as a preparation method and application of the high-viscosity anti-swelling tissue adhesive. The high-viscosity anti-swelling tissue adhesive is prepared from a part a and a part b, the part a comprises a cycloenone acetal monomer (CKA), an initiator and a cross-linking agent; and the part b comprises an olefin monomer, choline chloride and arginine. The adhesive provided by the invention is an injectable adhesive taking cycloenone acetal, an olefin monomer and a dihydrogen bond acceptor deep eutectic solvent (DES) as cores, choline chloride and arginine are synergistically used as a hydrogen bond acceptor, and the olefin monomer is used as a hydrogen bond donor to construct a high-viscosity DES pre-polymerized solution, so that the in-vivo anti-scouring property is remarkably improved, and the in-vivo anti-scouring property is improved; a hydrophobic network is formed through CKA ring opening polymerization, and long-term swelling resistance and stability are achieved; the adhesive is suitable for closing and bonding wounds in wet environments such as massive hemorrhage wounds, in-vivo wounds, bone tissues and the like. The adhesive also has excellent swelling resistance and tensile property.
Need to check novelty before this filing date? Find Prior Art

Description

TECHNICAL FIELD

[0001] The application belongs to the technical field of biomedical materials, and particularly relates to a high-viscosity anti-swelling tissue adhesive based on a dual-receptor deep eutectic solvent and a preparation method thereof. BACKGROUND

[0002] Injectable adhesives are an increasingly important tool in the medical field, especially in surgery and wound treatment, which provides an alternative to traditional suturing and stapling, can conform to irregular tissue surfaces, fill gaps, provide uniform sealing, and reduce dead space. It is especially suitable for minimally invasive treatment techniques to achieve closure of difficult-to-reach sites or delicate tissues such as internal organs, blood vessels, nerves, etc.

[0003] However, natural injectable adhesives such as fibrin glue have low bonding strength, and chemical adhesives such as cyanoacrylates have high bonding strength but are not degradable. Injectable adhesives based on cyclic alkenyl ketone acetal not only have strong bonding performance under physiological conditions, but also have degradability and anti-swelling properties. However, due to insufficient initial viscosity, the pre-polymer solution is washed away by blood flow or body fluids, such as a fibrin glue loss rate of >40%; due to water absorption and swelling, the long-term stability of the system is poor, such as a gelatin-based material swelling rate of >300%. SUMMARY

[0004] Therefore, the purpose of the present application is to provide a high-viscosity anti-swelling tissue adhesive based on a dual-receptor deep eutectic solvent and a preparation method thereof, which has high viscosity and pre-adhesion effect; and also has anti-swelling properties.

[0005] The present application provides a high-viscosity anti-swelling tissue adhesive based on a dual-receptor deep eutectic solvent, and the preparation raw materials include a portion a and a portion b.

[0006] The portion a includes a cyclic alkenyl ketone acetal monomer, an initiator and a crosslinking agent.

[0007] The portion b includes an olefin monomer, choline chloride and arginine.

[0008] Preferably, the molar ratio of the olefin monomer, choline chloride and arginine is (2-5):1:(1-2).

[0009] Preferably, the cyclic alkenyl ketone acetal monomer is selected from one or more of 2-methylene-1,3-dioxepane, 5,6-benzo-2-methylene-1,3-dioxepane and 2-methylene-4-phenyl-1,3-dioxolane.

[0010] Preferably, the olefin monomer is selected from one or more of acrylic acid, butyl acrylate, hydroxyethyl acrylate, methacrylic acid, hydroxymethyl methacrylate, hydroxyethyl methacrylate and 1-hydroxymethyl methacrylate.

[0011] Preferably, the mass ratio of the cyclic alkenone acetal monomer, initiator and crosslinking agent is (20-50):(0.1-5):(2-10).

[0012] The crosslinking agent is selected from one or more of polyethylene glycol diacrylate, dimethyl acrylate, methacrylamide and N-substituted methacrylamide.

[0013] Preferably, the molar ratio of the cyclic alkenone acetal monomer and the olefin monomer is 1:1-10.

[0014] The application provides a preparation method of the high-viscosity anti-swelling tissue adhesive based on the dual-receptor deep eutectic solvent, and the method comprises the following steps:

[0015] Mix the cyclic alkenone acetal monomer, initiator and crosslinking agent to obtain part a;

[0016] Blend the olefin monomer, choline chloride and arginine, and stir uniformly at 70-80 DEG C to obtain part b;

[0017] Mix the part a and part b uniformly to obtain the high-viscosity anti-swelling tissue adhesive.

[0018] The application provides an application of the high-viscosity anti-swelling tissue adhesive in the preparation of a tissue adhesive.

[0019] The application provides a high-viscosity anti-swelling tissue adhesive based on a dual-receptor deep eutectic solvent, and the preparation raw materials comprise part a and part b; the part a comprises a cyclic alkenone acetal monomer (CKA), an initiator and a crosslinking agent; and the part b comprises an olefin monomer, choline chloride (ChCl) and arginine (Arg). The adhesive provided by the application is an injectable adhesive taking a cyclic alkenone acetal (CKA), a vinyl monomer and a dual-hydrogen-bond receptor deep eutectic solvent (DES) as the core, taking choline chloride and arginine as the hydrogen-bond receptor in cooperation, taking an olefin monomer (such as acrylic acid AA) as the hydrogen-bond donor to construct a high-viscosity DES prepolymer liquid, significantly improving the in-vivo anti-washing property, and forming a hydrophobic network through CKA ring-opening polymerization to realize long-term anti-swelling and stability; and the adhesive is suitable for wound closure and bonding in a wet environment such as a large hemorrhagic wound, an in-vivo wound and a bone tissue. The adhesive also has excellent anti-swelling and tensile properties. BRIEF DESCRIPTION OF DRAWINGS

[0020] Figure 1Underwater Swelling Rate Column Chart of Adhesive Prepared for the Inventive Examples and Comparative Examples. DETAILED DESCRIPTION

[0021] The present application provides a high-viscosity anti-swelling tissue adhesive based on a dual-receptor deep eutectic solvent, and the preparation raw materials include a part and a b part.

[0022] The a part includes a cyclic ketene acetal monomer, an initiator and a crosslinking agent.

[0023] The b part includes an olefin monomer, choline chloride and arginine.

[0024] The present application provides a high-viscosity anti-swelling tissue adhesive based on a dual-receptor deep eutectic solvent, which is an injectable adhesive with cyclic ketene acetal (CKA), vinyl monomer and dual-hydrogen bond receptor deep eutectic solvent (DES) as the core.

[0025] The present application provides a high-viscosity anti-swelling tissue adhesive based on a dual-receptor deep eutectic solvent, and the preparation raw materials include a part and a b part.

[0026] The mass ratio of the cyclic ketene acetal monomer, the initiator and the crosslinking agent in the present application is (20-50):(0.1-5):(2-10).

[0027] The present application provides a high-viscosity anti-swelling tissue adhesive based on a dual-receptor deep eutectic solvent, and the preparation raw materials include a part and a b part.

[0028] The molar ratio of the olefin monomer, choline chloride and arginine in the application is (2-5):1:(1-2); in specific embodiments, the molar ratio of the hydroxyethyl methacrylate, choline chloride and arginine is 3:1:1, or 4:1:1, or 3:1:2, or 4:1:2. The guanidino group of the arginine in the application forms multiple hydrogen bonds and electrostatic interactions with the carboxyl / hydroxyl groups on the surface of the tissue, so that the adhesive has pre-adhesion. The arginine can promote cell migration and angiogenesis, so that the adhesive has biological activity; the arginine can inhibit Escherichia coli and Staphylococcus aureus, so that the adhesive has antibacterial activity, and the antibacterial rate is >85%; the guanidino group of the arginine forms multiple bonds with the carboxyl group of collagen, and the copolymer chain of the cyclic alkenone acetal and the olefin penetrates into the microstructure of the tissue to achieve mechanical interlocking, so that the adhesive has strong tissue adhesion.

[0029] The molar ratio of the cyclic alkenone acetal monomer and the olefin monomer in the application is 1:1-10, specifically 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, or 1:10, preferably 1:1.

[0030] The application provides a preparation method of the high-viscosity anti-swelling tissue adhesive based on the dual-receptor deep eutectic solvent according to the above technical solution, which comprises the following steps:

[0031] The cyclic alkenone acetal monomer, the initiator and the crosslinking agent are mixed to obtain part a;

[0032] The olefin monomer, choline chloride and arginine are blended and stirred uniformly at 70-80 DEG C to obtain part b;

[0033] The part a and the part b are mixed uniformly to obtain the high-viscosity anti-swelling tissue adhesive based on the dual-receptor deep eutectic solvent.

[0034] The adhesive prepared by the application has high viscosity and anti-swelling performance against body fluid flushing, and also has injectability, high tissue bonding strength, biocompatibility and degradability.

[0035] The preparation of part b in the application is carried out under stirring; preferably, a magnetic heating stirrer is used. The application adjusts the viscosity of the deep eutectic solvent by the proportion of the hydrogen bond donor, i.e. the DES prepolymer liquid; the viscosity of part b is 5000-8000 mPa·s at 25 DEG C; specifically, it can be 5000 mPa·s, 5500 mPa·s, 6000 mPa·s, 6500 mPa·s, 7000 mPa·s, 7500 mPa·s or 8000 mPa·s.

[0036] The application preferably adds a pharmaceutical component in part b, such as one or more of a healing-promoting external recombinant human epidermal growth factor, vitamins, and antibacterial drugs; the antibacterial drugs such as vancomycin, kanamycin, etc. The content of the pharmaceutical component added in part b is 0.5-10 wt%; specifically 0.5 wt%, 1 wt%, 1.5 wt%, 2 wt%, 2.5 wt%, 3 wt%, 3.5 wt%, 4 wt%, 4.5 wt%, 5 wt%, 5.5 wt%, 6 wt%, 6.5 wt%, 7 wt%, 7.5 wt%, 8 wt%, 8.5 wt%, 9 wt%, 9.5 wt%, or 10 wt%.

[0037] The low-polarity environment (polarity < 20) and high initial viscosity (> 500 mPa·s) of the DES in the application limit water diffusion; the zwitterionic nature of arginine further stabilizes the interfacial hydration layer.

[0038] The application provides a use of the high-viscosity anti-swelling tissue adhesive in the preparation of a tissue adhesive.

[0039] After the above-mentioned adhesive is injected into a wound site, due to its high viscosity and pre-adhesion effect, it can effectively adhere to the wound site in the presence of body fluids or blood without being washed away, thereby achieving effective adhesion and plugging of the wound site and achieving wound closure. When the adhesive is used on a wound site, it can quickly solidify, with a solidification time of 10-240 s, a lap shear tensile strength for bone tissue of 0.1-12 MPa, a lap shear tensile strength for soft tissue such as skin of 20-150 KPa, a lap bonding strength for bone tissue of 0.3-20 MPa, and a closure strength for soft tissue wounds of 15-120 KPa, exhibiting good soft and hard tissue bonding and closure performance. At the same time, the compressive modulus of the adhesive is 10-80 MPa, which can well match the modulus of the adhered bone tissue. At the same time, the hydrophobic properties of the DESs and the cyclic ketene acetal enable the adhesive to effectively exclude the hydration layer at the wound site, achieving effective contact between the adhesive and the interface. In addition, the in-situ polymerization system has dual anti-swelling properties, including a first stage: DES network limiting water penetration (instantaneous anti-swelling) and a second stage: CKA ring-opening polymerization to generate a polycaprolactone hydrophobic segment (long-term anti-swelling), which enables the adhesive to have good anti-swelling performance; the bonding strength of the adhered sample after 28 d of immersion can still reach 70% of the original bonding strength; the degradable performance enables the material to not hinder tissue repair, with a material degradation amount of ≥20% after 30 days of implantation and a degradation amount of ≥40% after 60 days, exhibiting good degradation performance of the material, which can well match the growth of bone tissue. Moreover, the degradation rate can be controlled by adjusting the types and proportions of the ring-opening monomers, the deep eutectic solvent, etc., matching the repair progress of the tissue, and gradually degrading and disappearing after the tissue regeneration is completed, avoiding the trouble of secondary surgery removal.

[0040] In order to further illustrate the present application, a high-viscosity anti-swelling tissue adhesive based on a dual-receptor deep eutectic solvent and a preparation method thereof provided by the present application are described in detail below in conjunction with examples, but they cannot be understood as limiting the protection scope of the present application.

[0041] In the following examples, the initiator is benzoyl peroxide (BPO) and N,N-dimethyl-p-toluidine (DmpT--activator), and the molar ratio between the two is 1:1.

[0042] Example 1

[0043] 1) 2-methylene-1,3-dioxepane (MDO) monomer, initiator and crosslinking agent polyethylene glycol diacrylate with a mass ratio of 30:2:5 are uniformly mixed to obtain a part solution;

[0044] 2) The hydrogen bond donor olefin monomer hydroxyethyl methacrylate and the dual hydrogen bond acceptor choline chloride and arginine are placed in a volumetric flask in a molar ratio of 3:1:1, mixed uniformly, and heated and stirred on a magnetic stirrer at 70°C until a uniform b solution is obtained;

[0045] 3) The a solution is added to the b solution, and the molar ratio of MDO to olefin monomer is 1:1, and the mixture is uniformly mixed to form a high-viscosity anti-swelling tissue adhesive.

[0046] Example 2

[0047] 1) 2-methylene-1,3-dioxepane (MDO) monomer, initiator and crosslinking agent polyethylene glycol diacrylate with a mass ratio of 30:0.5:2.5 are uniformly mixed to obtain a part solution;

[0048] 2) The hydrogen bond donor olefin monomer hydroxyethyl methacrylate and the dual hydrogen bond acceptor choline chloride and arginine are placed in a volumetric flask in a molar ratio of 4:1:1, mixed uniformly, and heated and stirred on a magnetic stirrer at 70°C until a uniform b solution is obtained;

[0049] 3) The a solution is added to the b solution, and the molar ratio of MDO to olefin monomer is 1:2, and the mixture is uniformly mixed to form a high-viscosity anti-swelling tissue adhesive.

[0050] Example 3

[0051] 1) 2-methylene-1,3-dioxepane (MDO) monomer, initiator and crosslinking agent polyethylene glycol diacrylate with a mass ratio of 30:0.5:2.5 are uniformly mixed to obtain a part solution;

[0052] 2) Hydrogen bond donor olefinic monomer hydroxyethyl methacrylate and double hydrogen bond acceptor choline chloride and arginine were put into a volumetric flask in a molar ratio of 3:1:2, mixed well, and heated on a magnetic stirrer at 70°C for continuous heating and stirring until a uniform b solution was obtained;

[0053] 3) The a solution was added to the b solution, with a molar ratio of MDO to olefinic monomers of 1:1, mixed well, and a high-viscosity anti-swelling tissue adhesive was formed.

[0054] Example 4

[0055] 1) The mass ratio of 30:0.5:2.5 of cycloalkenone acetal monomer 2-methylene-1,3-dioxepane (MDO) monomer, initiator and crosslinking agent polyethylene glycol diacrylate were mixed well to obtain a part solution;

[0056] 2) Hydrogen bond donor olefinic monomer hydroxyethyl methacrylate and double hydrogen bond acceptor choline chloride and arginine were put into a volumetric flask in a molar ratio of 4:1:2, mixed well, and heated on a magnetic stirrer at 70°C for continuous heating and stirring until a uniform b solution was obtained;

[0057] 3) 3wt% of the antibacterial drug vancomycin was added to the b part;

[0058] 4) The a solution was added to the b solution, with a molar ratio of MDO to olefinic monomers of 1:2, mixed well, and a high-viscosity anti-swelling tissue adhesive was formed.

[0059] Comparative Example 1

[0060] Unlike Example 1, no DESs were added.

[0061] Comparative Example 2

[0062] Unlike Example 1, the hydrogen bond donor in the DESs did not contain arginine.

[0063] The adhesives prepared in Examples 1-4 and Comparative Examples 1-2 were tested for performance:

[0064] 1. Adhesion strength test

[0065] According to GB / T 7124-2008 standard, the in vitro adhesive strength is obtained by shear bonding test, taking pig skin bonding as an example. Before the experiment, the fat-removed pig skin and bone pieces are cut into regular plate-shaped samples, with a length of 10 cm, a width of 2.5 cm and a thickness of 0.2 cm; the mixed solution is quickly and uniformly coated on the fat-removed pig skin and bone pieces, and another sample of the same kind is covered on it, and is slightly pressed for more than 20 s, and free radical ring-opening polymerization bonding occurs at room temperature; the bonding area is 2.5 cm x 1.0 cm; the prepared bonding sample is placed at room temperature for 2 h, and then tensile test is performed on a universal testing machine (LLOYD company LD-5 type, sensor is 2.5 kN), the tensile rate is 5 mm / min, and the shear bonding strength is calculated by dividing the load force at the time of breaking of the bonding sample by the bonding area.

[0066] Table 1: In vitro adhesive strength

[0067]

[0068] The results show that, compared with Comparative Examples 1-2, the tissue adhesive material containing deep eutectic solvent in Examples 1-4 has better mechanical properties; among them, the guanidino group of Arg in DES forms a hydrogen bond with the carboxyl group of AA, and ChCl provides a positive charge to enhance tissue adsorption, so as to better match the mechanical requirements of tissue adhesion closure.

[0069] 2. Adhesive strength test in water environment

[0070] Due to the presence of body fluids and blood in the physiological environment, a layer of hydration layer exists on the adhered interface, which hinders the close contact between the adhesive and the tissue interface, and the subsequent adhesive performance. Especially when the blood flow is large, the injectable adhesive with high fluidity will be washed away by the blood flow, thereby affecting the adhesive strength. The adhesive system containing DES has high viscosity, which can effectively pre-adhere to the tissue surface under the condition of body fluids and blood, thereby avoiding the influence of blood flow flushing. The shear adhesive strength of the adhesive to pig skin and cow bone in water environment is determined by using a universal testing machine.

[0071] Table 2: In vitro underwater adhesive strength

[0072]

[0073]

[0074] The results show that, compared with Comparative Examples 1-2, the tissue adhesive material containing deep eutectic solvent in Examples 1-4 has better mechanical properties; ChCl provides a positive charge for electrostatic adsorption, and the guanidino group of Arg enhances tissue adhesion, thereby synergistically improving the anti-washing capacity; the anti-washing principle is: high-viscosity DES network → resistance to shear force of body fluids → retention of wound surface, so as to meet the adhesion requirements in high body fluid and blood environment.

[0075] 3. Swelling ratio test

[0076] The adhesive sample was lyophilized or oven dried at 105°C to constant weight (W0), immersed in simulated body fluid (e.g. normal saline, phosphate buffer), and kept at constant temperature (usually 37°C) until swelling equilibrium. After removal, the surface free liquid was quickly blotted with filter paper (≤30 seconds), and weighed (W s );

[0077] The swelling ratio of the adhesive was calculated according to the following formula:

[0078]

[0079] The test results are shown in Table 2: Figure 1 Figure 1 It can be seen that the tissue adhesive material containing deep eutectic solvent in Examples 1-4 has better anti-swelling performance than Comparative Examples 1-2; the anti-swelling performance of Comparative Example 1 is also very good, which is attributed to the polyester hydrophobic segment formed by ring enone acetal monomer ring-opening polymerization, which inhibits late swelling; indicating that the material has good anti-swelling performance in the liquid and good compatibility.

[0080] 4. Tensile properties after swelling

[0081] The effect of swelling on the function of the adhesive needs to be evaluated by mechanical and interfacial properties. The adhesive is coated on the sample, and then the adhered sample is completely immersed in the simulated body fluid until equilibrium, ensuring that the samples and the container wall are not in contact (a hook can be used); swell to equilibrium at 37°C, quickly remove the sample; quickly and gently wipe the surface residual liquid with a clean filter paper or cloth (time not more than 30 seconds), and the control group remains dry; perform tensile or peel tests according to ASTM F2258, and record the strength values (P0: initial, Ps: after swelling), and the adhesive strength loss rate test formula is as follows:

[0082]

[0083] The test results of swelling are shown in Table 3:

[0084] Table 3: Tensile properties of the material after swelling

[0085]

[0086]

[0087] ​The results show that, compared with Comparative Examples 1-2, the dynamic interaction provided by the deep eutectic solvent in Examples 1-4 makes the tensile properties of the tissue adhesive material better; the anti-swelling performance of Comparative Example 1 is also very good, which is attributed to the hydrophobic chain segment of the polyester formed by ring ketolactone monomer ring-opening polymerization, which inhibits late swelling; the change in tensile properties is due to swelling, which usually leads to a decrease in tensile strength.

[0088] From the above examples, the present application provides a high-viscosity anti-swelling tissue adhesive based on a dual-receptor deep eutectic solvent, which is prepared from a part a and a part b; the part a includes a ring ketolactone monomer (CKA), an initiator and a crosslinking agent; the part b includes an olefin monomer, choline chloride (ChCl) and arginine (Arg). The adhesive provided by the present application is an injectable adhesive based on a ring ketolactone (CKA), a vinyl monomer and a dual-hydrogen bond receptor deep eutectic solvent (DES) as the core, with choline chloride and arginine as the hydrogen bond receptor, and an olefin monomer (such as acrylic acid AA) as the hydrogen bond donor to construct a high-viscosity DES prepolymer solution, which significantly improves the in-vivo anti-washing property, and forms a hydrophobic network through CKA ring-opening polymerization to achieve long-term anti-swelling and stability; it is suitable for wound closure and bonding in wet environments such as large hemorrhagic wounds, in-vivo wounds and bone tissues. The adhesive also has excellent anti-swelling and tensile properties. Experimental results show that the viscosity of the DES prepolymer solution is 5000-8000 mPa·s (25℃), which is 80 times higher than that of traditional aqueous solutions (<100 mPa·s); the swelling rate is <120%; under a water environment, the shear adhesive strength of the adhesive to pigskin is 145-160 KPa, and the shear adhesive strength to bovine bone is 13-15 MPa.

[0089] The above only describes the preferred embodiments of the present application, and it should be noted that for those skilled in the art, without departing from the principles of the present application, a number of improvements and refinements can be made, which should also be considered within the scope of protection of the present application.

Claims

1. A high-viscosity anti-swelling tissue adhesive based on a dual-receptor deep eutectic solvent, the raw materials of which include part a and part b; Part a includes cycloenone acetal monomers, initiators, and crosslinking agents; Part b includes olefin monomers, choline chloride, and arginine.

2. The high-viscosity anti-swelling tissue adhesive according to claim 1, characterized in that, The molar ratio of the olefin monomer, choline chloride and arginine is (2-5):1:(1-2).

3. The high-viscosity anti-swelling tissue adhesive according to claim 1, characterized in that, The cycloenone acetal monomers are selected from one or more of 2-methylene-1,3-dioxane, 5,6-benzo-2-methylene-1,3-dioxane, and 2-methylene-4-phenyl-1,3-dioxolane.

4. The high-viscosity anti-swelling tissue adhesive according to claim 1, characterized in that, The olefin monomers are selected from one or more of acrylic acid, butyl acrylate, hydroxyethyl acrylate, methacrylic acid, hydroxymethyl methacrylate, hydroxyethyl methacrylate, and 1-hydroxymethacrylate.

5. The high-viscosity anti-swelling tissue adhesive according to claim 1, characterized in that, The mass ratio of the cycloenone acetal monomer, initiator, and crosslinking agent is (20-50):(0.1-5):(2-10).

6. The high-viscosity anti-swelling tissue adhesive according to claim 1, characterized in that, The molar ratio of the cycloenone acetal monomer to the olefin monomer is 1:1 to 10.

7. The high-viscosity anti-swelling tissue adhesive according to claim 1, characterized in that, The crosslinking agent is selected from one or more of polyethylene glycol diacrylate, dimethacrylate, methacrylamide, and N-substituted methacrylamide.

8. The high-viscosity anti-swelling tissue adhesive according to claim 1, characterized in that, The initiator is selected from benzoyl peroxide and / or N,N-dimethyl-p-toluidine.

9. A method for preparing a high-viscosity anti-swelling tissue adhesive based on a dual-receptor deep eutectic solvent as described in any one of claims 1 to 8, comprising the following steps: Part a is obtained by mixing cycloenone acetal monomers, initiators, and crosslinking agents. The olefin monomer, choline chloride and arginine were mixed and stirred evenly at 70-80°C to obtain part b. The a and b parts are mixed evenly to obtain a high-viscosity anti-swelling tissue adhesive.

10. The use of the high viscosity anti-swelling tissue adhesive according to any one of claims 1 to 8 in the preparation of tissue adhesives.